The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The collaboration between the two companies is bearing fruit, it is the first-ever version of this class. It received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).
“The marketing authorisation for this insulin glargine product in Europe is a significant achievement for the Lilly-Boehringer Ingelheim Alliance. We believe that insulin glargine will continue to be widely used for many years, and Lilly and Boehringer Ingelheim are committed to addressing the needs of people living with diabetes and providing support beyond the medicine,” said Enrique Conterno, president, Lilly Diabetes.
The Alliance’s insulin glargine product called “Abasria” is a basal insulin with the same amino acid sequence as Lantus® (insulin glargine by Sanofi) and is intended to provide long-lasting blood sugar control between meals and at night. It is called a biosimilar,